Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Drivers of AR indifferent anti-androgen resistance in prostate cancer cells.

Handle F, Prekovic S, Helsen C, Van den Broeck T, Smeets E, Moris L, Eerlings R, Kharraz SE, Urbanucci A, Mills IG, Joniau S, Attard G, Claessens F.

Sci Rep. 2019 Sep 24;9(1):13786. doi: 10.1038/s41598-019-50220-1.

2.

AR variants: lost in translation to clinical practice?

Handle F, Claessens F.

Nat Rev Urol. 2019 Aug;16(8):451-452. doi: 10.1038/s41585-019-0204-4. No abstract available.

PMID:
31182854
3.

Molecular underpinnings of enzalutamide resistance

Prekovic S, van den Broeck T, Linder S, van Royen ME, Houtsmuller AB, Handle F, Joniau S, Zwart W, Claessens F.

Endocr Relat Cancer. 2018 Nov 1;25(11):R545–R557. doi: 10.1530/ERC-17-0136.

PMID:
30306781
4.

The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models.

Handle F, Puhr M, Schaefer G, Lorito N, Hoefer J, Gruber M, Guggenberger F, Santer FR, Marques RB, van Weerden WM, Claessens F, Erb HHH, Culig Z.

Mol Cancer Ther. 2018 Dec;17(12):2722-2731. doi: 10.1158/1535-7163.MCT-18-0508. Epub 2018 Sep 25.

PMID:
30254184
5.

Fractionated Radiation of Primary Prostate Basal Cells Results in Downplay of Interferon Stem Cell and Cell Cycle Checkpoint Signatures.

Guggenberger F, van de Werken HJG, Erb HHH, Cappellano G, Trattnig K, Handle F, Peer S, Schäfer G, Jenster G, Culig Z, Skvortsova I, Santer FR.

Eur Urol. 2018 Dec;74(6):847-849. doi: 10.1016/j.eururo.2018.06.002. Epub 2018 Jun 18. No abstract available.

PMID:
29914715
6.

Effects of Intravitreal Aflibercept on Galectin-1 and Vascular Endothelial Growth Factor-A Plasma Levels in Patients with Diabetic Retinopathy.

Waltl I, Zehetner C, Seifarth C, Handle F, Kieselbach GF, Angermann R, Kralinger MT.

Curr Eye Res. 2018 Mar;43(3):368-375. doi: 10.1080/02713683.2017.1403632. Epub 2017 Nov 27.

PMID:
29172741
7.

The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy.

Puhr M, Hoefer J, Eigentler A, Ploner C, Handle F, Schaefer G, Kroon J, Leo A, Heidegger I, Eder I, Culig Z, Van der Pluijm G, Klocker H.

Clin Cancer Res. 2018 Feb 15;24(4):927-938. doi: 10.1158/1078-0432.CCR-17-0989. Epub 2017 Nov 20.

8.

The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling.

Nappo G, Handle F, Santer FR, McNeill RV, Seed RI, Collins AT, Morrone G, Culig Z, Maitland NJ, Erb HHH.

Oncogenesis. 2017 May 29;6(5):e342. doi: 10.1038/oncsis.2017.23.

9.

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.

Hoefer J, Akbor M, Handle F, Ofer P, Puhr M, Parson W, Culig Z, Klocker H, Heidegger I.

Oncotarget. 2016 Sep 13;7(37):59781-59794. doi: 10.18632/oncotarget.10926.

10.

The AR/NCOA1 axis regulates prostate cancer migration by involvement of PRKD1.

Luef B, Handle F, Kharaishvili G, Hager M, Rainer J, Janetschek G, Hruby S, Englberger C, Bouchal J, Santer FR, Culig Z.

Endocr Relat Cancer. 2016 Jun;23(6):495-508. doi: 10.1530/ERC-16-0160. Epub 2016 Jun 2.

11.

SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells.

Handle F, Erb HH, Luef B, Hoefer J, Dietrich D, Parson W, Kristiansen G, Santer FR, Culig Z.

Mol Cancer Res. 2016 Jun;14(6):574-85. doi: 10.1158/1541-7786.MCR-15-0495. Epub 2016 Apr 6.

12.

PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer.

Puhr M, Hoefer J, Eigentler A, Dietrich D, van Leenders G, Uhl B, Hoogland M, Handle F, Schlick B, Neuwirt H, Sailer V, Kristiansen G, Klocker H, Culig Z.

Oncogene. 2016 May 5;35(18):2322-32. doi: 10.1038/onc.2015.292. Epub 2015 Aug 10.

13.

Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy.

Santer FR, Erb HH, Oh SJ, Handle F, Feiersinger GE, Luef B, Bu H, Schäfer G, Ploner C, Egger M, Rane JK, Maitland NJ, Klocker H, Eder IE, Culig Z.

Oncotarget. 2015 Mar 20;6(8):6105-22.

14.

IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9.

Erb HH, Langlechner RV, Moser PL, Handle F, Casneuf T, Verstraeten K, Schlick B, Schäfer G, Hall B, Sasser K, Culig Z, Santer FR.

Endocr Relat Cancer. 2013 Aug 23;20(5):677-89. doi: 10.1530/ERC-13-0222. Print 2013 Oct.

15.

Inhibition of hepatic scavenger receptor-class B type I by RNA interference decreases atherosclerosis in rabbits.

Demetz E, Tancevski I, Duwensee K, Stanzl U, Huber E, Heim C, Handle F, Theurl M, Schroll A, Tailleux A, Dietrich H, Patsch JR, Eller P, Ritsch A.

Atherosclerosis. 2012 Jun;222(2):360-6. doi: 10.1016/j.atherosclerosis.2012.03.012. Epub 2012 Mar 23.

16.

On the use of frequency-domain reconstruction algorithms for photoacoustic imaging.

Schulze R, Zangerl G, Holotta M, Meyer D, Handle F, Nuster R, Paltauf G, Scherzer O.

J Biomed Opt. 2011 Aug;16(8):086002. doi: 10.1117/1.3605696.

Supplemental Content

Loading ...
Support Center